ClinicalTrials.Veeva

Menu
The trial is taking place at:
H

Hope Clinical Research | Canoga Park, California

Veeva-enabled site

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Concert Pharmaceuticals logo

Concert Pharmaceuticals

Status and phase

Active, not recruiting
Phase 3
Phase 2

Conditions

Alopecia Areata

Treatments

Drug: CTP-543

Study type

Interventional

Funder types

Industry

Identifiers

NCT03898479
CP543.5001

Details and patient eligibility

About

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Enrollment

1,000 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial

Exclusion criteria

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
  • Donation of blood at any point throughout the study and for 30 days after last dose of study medication

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

1,000 participants in 1 patient group

CTP-543
Experimental group
Description:
Patients who previously completed a qualifying CTP-543 clinical trial
Treatment:
Drug: CTP-543

Trial contacts and locations

91

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems